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Subjective-symptom tools used in dermatology have ra-
rely been experimentally tested for cognitive “focus” and 
“framing” biases. We investigated the effects of affective 
biases on the Dermatology Life Quality Index (DLQI), 
the Global Health Question and visual analogue scores. 
Two experiments tested the response to affect-eliciting 
ZRUGV DQG ¿OP :H GHPRQVWUDWHG QR VLJQL¿FDQW GLI-
ference in median DLQI scores for subjects exposed to 
negative vs. neutral words (medians 8.5 and 9.5, respec-
tively), or negative vs. positive words (medians 6.0 and 
9.0, respectively, overall p = 0.41.) Median DLQI scores 
were similar for groups who had (8.0), or had not (9.0), 
seen a video clip about a severe skin condition (p = 0.34). 
Finally, we compared an Amended DLQI (ADLQI), the 
DLQI re-worded into neutral “frames”, with the stan-
dard DLQI. ADLQI median scores were higher (ADLQI 
'/4,EXWQRWVLJQL¿FDQWO\VR p = 0.47). We 
have been unable to demonstrate any effects of the biases 
studied, but the statistical power of our study is modest. 
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It is widely accepted that objective measures of disease 
EDVHGRQSDWKRELRORJLFDO YDULDEOHV DUH LQVXI¿FLHQW WR
measure the personal impact of disease. There are at 
least two reasons for this. First, we do not have objective 
correlates of many states, such as pain or itch (1, 2), and 
secondly, how the disease process affects an individual 
person will depend on a range of individual and con-
textual factors. For instance, the visibility of extensive 
psoriasis may be a greater burden to an individual who 
likes to go swimming, than to an individual who never 
goes swimming. Another example is that a person who 
previously had very severe disease, for instance bad 
childhood eczema, will use that as a comparator for 
their present state: their current disease state might be 
viewed differently if there was no previous history of 
skin disease (3).
In recent years, a number of tools have been develo-
ped with the goal of measuring the functional burden of 
disease as experienced by the patient. Examples include 
the Global Health Questionnaire (GHQ), which has 
been used to provide an overall assessment of patient-
perceived health (4), whilst another generic tool, the 
visual analogue scale (VAS), has been used as a measure 
of a range of symptoms such as itch or pain (5–7). For 
skin disease, one of the most widely used tools is the 
Dermatology Life Quality Index (DLQI) (8, 9). The 
designers of the tool had practicality in mind – it was 
considered a priority that the tool should be short and 
quick to answer, in order to aid assessment during clinic 
visits, and thus this 10-question tool was designed. In 
a medical and economic climate where resources are 
scarce, the assessment of quality of life and how it 
PD\EHLQÀXHQFHGE\PHGLFDOLQWHUYHQWLRQKDVEHFRPH
a major research programme. In England, the British 
Association of Dermatologists and the National Institute 
of Health and Clinical Excellence (NICE) has advoca-
ted the use of the DLQI as a disease assessment tool 
for patients with psoriasis, to determine whether they 
should receive certain expensive biological therapies 
(10) (http://www.nice.org.uk/Guidance/TA134).
Work over the last 25 years, in cognitive psychology 
DQGHVSHFLDOO\ LQ WKH¿HOGRIKDSSLQHVV UHVHDUFKKDV
revealed a number of problems surrounding the measu-
rement of subjective states, quality of life and utility (for 
reviews, see Kahneman et al. (11)). First, and strange 
as it may initially appear, individuals may not be able 
to access their own feelings (12, 13), and the way in 
ZKLFKLQIRUPDWLRQLVJDWKHUHGPD\DOWHURULQÀXHQFH
the patient’s own perception of their own feelings (3, 
14–16). Secondly, a number of cognitive limitations 
may limit the value of subjective knowledge: patients 
may not be able to remember changes in their functional 
status, nor predict the effects of particular interventions 
or change in state (12, 13, 17–19). 
In the present paper, we set out to explore the effects 
of contextual or “framing” biases on commonly used 
subjective measures including the DLQI in dermatology. 
We use the term “framing bias” widely to include bias 
that stems from how the feeling, emotion or symptom is 
enquired about. Questions can be “framed” in language 
or presented in a context that may elicit a stereotyped 
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answer; for instance, by implying that an aspect of di-
sease should be considered as a negative phenomenon, 
leading a respondent to consider this aspect as negative 
where they did not before (3). Secondly, the immediate 
context may alter how individuals perceive their own 
symptoms. For example, patients frequently anchor or 
skew their own assessment of disease by reference to 
others who they think are less or more fortunate (3, 5).
We therefore designed three experiments in which 
either the wording of the DLQI was altered, or the 
immediate context in which individuals completed the 
DLQI, GHQ or VAS for common symptoms was mani-
pulated. The manipulation was performed using video, 
listing of negative or neutral words, and alterations in 
the actual wording of the DLQI.
METHODS
Participants
An opportunistic sample of 215 patients was recruited. Because 
of the absence of similar prior work, formal power calculations 
were not performed. For each study, consecutive patients who 
agreed to take part were enrolled from the Royal Infirmary’s 
Department of Phototherapy in Edinburgh. Details of specific 
diagnoses were not sought, the usual throughput of the pho-
totherapy department would suggest that the majority (70%) 
of the patients had psoriasis, a minority (approximately 10%) 
had eczema and 20% other conditions (for instance generalized 
pruritus). Ethics committee approval was granted by the Lothian 
Ethics Committee (LREC reference: 06/S1104/56). 
All study procedures and patient interactions were conducted 
using a consistent, written script. The interaction script and 
subject information sheet explained that the studies were to 
determine which sort of questionnaire or score was most accu-
rate in assessing symptoms. The interventions were described in 
general terms (“You will be given a list of words to memorise” 
or “If you are randomised into a certain group you may see a 
film broadcast on terrestrial television”) in order to minimize 
unintentional “unblinding”.
All participants completed the GHQ (“In general, for someone 
of your age, would you say that your health is excellent, very 
good, good or poor?”), DLQI and VAS of disease extent, itch and 
insomnia, always in the same order. The DLQI is a 10-question 
tool, the score of which is acquired by summing the score for 
each question. The higher the DLQI score, the more severely their 
quality of life is affected (maximum score 30.) Most participants 
scored in the region of 6–10, which equates to a “moderate” effect 
of the skin condition on the quality of life.
Experiment 1
Our hypothesis was that, if subjects were exposed to certain 
mood-eliciting words, they would affect the subjective score 
accordingly, for instance, if they had read negative words, their 
subjective scores would suggest worse disease.
Forty patients were randomized into two groups. Group 1 were 
asked to read 10 negative words, had one minute to memorize 
them and were then asked to write them out. After this, they com-
pleted the GHQ, DLQI and the VAS of disease extent for both itch 
and insomnia. Group 2 went through an identical process, but the 
SDUWLFLSDQWVZHUHJLYHQDOLVWRIQHXWUDOZRUGVFHUWDLQ¿HOGV
RISV\FKRORJ\UHVHDUFKKDYHLGHQWL¿HGDQGXVHZRUGVWKDWHOLFLW
certain affective states.) The words for this part of the experiment 
are listed in Table I and were taken from the “Balanced Affective 
Word List” (http://www.sci.sdsu.edu/CAL/wordlist/origwordlist.
html). The words were matched with respect to total character 
and syllable length. A further 41 patients were randomized into 
two groups. Group 3 were asked to read 10 negative words 
and then write them out (without the necessity of memorizing 
them). The participants then completed GHQ, DLQI and VAS 
or disease extent, itching and insomnia. Group 4 went through 
an identical process, except participants were given a list of 10 
positive words. These words were taken from the University of 
Florida’s NIMH Centre for the Study of Emotion and Attention 
(http://csea.phhp.ufl.edu/Media.html#bottommedia) and are 
listed in Table I. The source of affect-eliciting words was altered 
as this afforded a larger scope of words with more recent and 
more extensive validation. Again, the words were matched for 
total character and syllable length.
Experiment 2
Our hypothesis was that if a subject saw a film highlighting 
the negative aspects of having a skin disease, then this would 
make them focus on the negative aspects of living with their 
skin disease and so their subjective scores would imply that 
they had worse disease. 
Fifty-four patients were randomized into two groups, with 
Group 1 completing GHQ then VAS for disease extent, itch and 
insomnia, after having watched a 10-min clip from a terrestrial 
television broadcast (“Real Families: My Skin Could Kill Me”, 
which was broadcast before the “watershed” on ITV1 in October 
2005) about living with the severe skin condition, Harlequin 
ichthyosis. Group 2 just completed the subjective tools without 
having watched the television clip. All subjects were questioned 
in the same way and in the same experimental room, whether 
or not they had watched the film. The randomization result 
(to watch the film or not) was included in the questionnaire 
envelope and was opened, with the interviewer present in the 
study room, the interviewer then adopted the appropriate script 
(for whether or not the participant was to watch the film) from 
that point. 
Table I. Experiment 1: words presented to each intervention group
Negative words 
(Group 1)
Neutral words 
(Group 2)
Positive words 
(Group 3)
Negative words 
(Group 4)
worry
ashamed
gloom
bad
sick
suffering
unhappy
itch
misery
rejected
wagon
aluminium
green
bus
scan
submarine
vitamin
iron
margin
resident
angel
birthday
beauty
caress
cheer
freedom
glory
humour
home
joke
mother
pretty
passion
reward
romantic
sun
sexy
snuggle
treasure
triumph
abuse
bankrupt
betray
cancer
cruel
funeral
gloom
hatred
hurt
jail
misery
poison
pollute
rabies
rejected
sad
sick
suicide
terrible
tragedy
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Experiment 3
In this study, our hypothesis was that if the DLQI focused on 
negative aspects of disease, then re-framing it into “neutral” 
frames should result in scores implying a better quality of life. 
We also hypothesized that if the DLQI focused on the negative, 
then this may negatively affect the responses to other subjective 
symptom scores. 
Eighty patients were randomized into two groups and each 
of these two groups further split into two sub-groups, giving a 
total of four sub-groups. Half the subjects answered the GHQ 
and standard DLQI, whilst the other half answered an altered 
DLQI (ADLQI) and the standard GHQ. The ADLQI mirrored 
the standard DLQI, but an attempt was made for each question 
to be re-written in a neutral frame, thereby, minimizing the 
possibility of a positive or negative framing and potentially 
reducing the possibility of a stereotyped answer. The ADLQI 
is shown in the electronic appendix (http://adv.medicaljournals.
se/article/abstract/10.2340.00015555-0768/app1). Division of 
the two groups allowed the ordering of the examination to be 
PDQLSXODWHGZLWKKDOIWKHVXEMHFWVUHFHLYLQJWKH*+4¿UVWDQG
then either the DLQI or the ADLQI, with the other half receiving 
the GHQ second.
Demographic variables including age and sex, together with 
the results, were de-identified and recorded in Excel. Statistical 
analyses were undertaken using R-software (http://www.R-
project.org (20)). 
RESULTS
Examination of raw data, not surprisingly, showed 
that the majority of variables were non-normally dist-
ributed. Medians were therefore compared using the 
Kruskal-Wallis (KW) analysis of variance (ANOVA), 
or for count data, Fisher’s exact test for r × c contin-
JHQF\WDEOHV)RUPDOVLJQL¿FDQFHZDVWDNHQDWp < 0.05. 
Because of the limited range of the GHQ questionnaire, 
results were also examined using Fisher’s exact test, 
but this did not alter any of the conclusions and is not 
presented.
Experiment 1
The impact of affect-eliciting words. A total of 81 sub-
jects were studied and their characteristics are shown in 
Table II. There were four intervention groups, numbe-
UHG±DVPHQWLRQHGDERYH7KHUHZHUHQRVLJQL¿FDQW
differences in the sex allocation (Fishers test, p = 0.81) 
nor median ages (Kruskal-Wallis, p = 0.70) between 
the four groups. Median scores for the four groups and 
p-values using the Kruskal-Wallis ANOVA are shown 
LQ7DEOH,,$VFDQEHVHHQWKHUHDUHQRVLJQL¿FDQWGLI-
ferences evident.
Experiment 2
7KHLPSDFWRIZDWFKLQJD¿OPDERXWOLYLQJZLWKDVHYHUH
skin condition. A total of 54 subjects were studied. 
Their characteristics and the median group-scores and 
Kruskal-Wallis ANOVA are shown in Table III. 
7KHUHZDV QR VLJQL¿FDQW VH[ GLIIHUHQFH EHWZHHQ
the two groups, those who were shown the video and 
those who were not (Fisher, p = 0.27). The median age 
of those shown the video was 52 compared with those 
who were not shown the video of 33; a difference that 
LVKLJKO\VLJQL¿FDQW.:p = 0.001). However, scatter 
plots did not show any obvious correlation between 
Table II. Experiment 1: subject characteristics, median scores and p-values of Kruskal-Wallis analysis of variance (ANOVA)
Age, years
mean (range) M/F
Median DLQI
(interquartile range)
Median GHQ
(interquartile range)
Median VAS (interquartile range)
Extent Itch Insomnia
Group 1 (Neg) 
n = 20
39.8 (17–71) 12/8 8.50 (5.00–11.75) 2.00 (1.00–2.00) 3.60 (2.80–5.60) 2.15 (0.90–4.33) 3.60 (1.50–7.20)
Group 2 (Neut) 
n = 20
41.4 (18–68) 9/11 9.50 (5.75–14.25) 2.00 (2.00–2.00) 3.70 (1.80–5.30) 2.15 (1.08–4.40) 4.80 (2.85–5.73)
Group 3 (Neg) 
n = 19
39.0 (20–72) 10/9 6.00 (2.00–10.50) 2.00 (2.00–3.00) 2.50 (0.60–5.00) 1.50 (0.55–3.95) 1.90 (0.70–5.75)
Group 4 (Pos) 
n = 22
37.4 (16–74) 11/11 9.00 (2.25–12.50) 2.00 (2.00–3.00) 4.80 (2.50–7.50) 1.30 (0.40–3.00) 3.40 (1.30–6.00)
p = Kruskal-Wallis 0.41 0.44 0.35 0.46 0.27
DLQI: Dermatology Life Quality Index; GHQ: Global Health Question; VAS: visual analogue scale.
Table III. Experiment 2: subject characteristics, median scores and p-values for Kruskal-Wallis analysis of variance (ANOVA)
Age, years 
mean (range)
Sex 
M/F
Median DLQI
(interquartile range)
Median GHQ
(interquartile range)
Median VAS (interquartile range)
Extent Itch Insomnia
Group 1 (video)
n = 27
50.3 (17–77) 14/13 8.00 (4.50–9.00 3.00 (2.00–3.00) 4.50 (2.95–6.15) 2.00 (0.85–3.90) 3.90 (2.10–6.35)
Group 2 (no video)
n = 27
35.8 (16–74) 9/18 9.00 (4.50–15.00) 2.00 (1.50–3.00) 3.20 (1.65–6.40) 2.70 (0.95–5.15) 2.20 (1.45–5.05)
p = Kruskal-Wallis 0.34 0.20 0.50 0.11 0.21
DLQI: Dermatology Life Quality Index; GHQ: Global Health Question; VAS: visual analogue scale.
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age and the outcome measures, so this difference was 
ignored. Median scores and p-values for the Kruskal-
Wallis ANOVA are shown in Table IV. As can be seen, 
WKHUHDUHQRVLJQL¿FDQWGLIIHUHQFHVHYLGHQW
Experiment 3
Re-wording DLQI into neutral frames. A total of 80 
subjects were studied and their characteristics are 
summarized in Table IV. GHQ and quality of life sco-
res (QI) were examined following four “treatments”. 
7KH¿UVW³WUHDWPHQW´ WKH'/4,ZDVFRPSDUHGZLWK
the second “treatment”, ADLQI and, following this, 
the ordering of GHQ and DLQI/ADLQI were studied 
(hence treatment groups were numbered as follows: 1, 
2 (DLQI) and 3, 4 (ADLQI.) 
7KHUHZHUHQRVLJQL¿FDQWGLIIHUHQFHVLQVH[)LVKHU
p = 0.17) or age (KW, p = 0.92) between the four groups. 
Median scores and Kruskal-Wallis ANOVA across the 
four groups for QI (DLQI and ADLQI) and GHQ are 
OLVWHGLQ7DEOH,97KHVHGLIIHUHQFHVDUHQRWVLJQL¿FDQW
(KW for QI p = 0.47 and GHQ p = 0.76). The ordering 
had no effect on GHQ (p = 0.60) or QI (p = 0.5) scores 
and therefore groups 1 and 2, and 3 and 4 were com-
bined. Medians for the ADLQI and the DLQI for these 
combined groups were 8.5 and 7, respectively, a dif-
IHUHQFHWKDWZDVFORVHWRVWDWLVWLFDOVLJQL¿FDQFHZLWKD
p-value of 0.07 (Kruskal-Wallis test).
DISCUSSION
The results presented are, essentially, negative and, 
in that sense, they can be viewed as reassuring. Using 
WKHFULWHULDRIVWDWLVWLFDOVLJQL¿FDQFHZHZHUHXQDEOHWR
VLJQL¿FDQWO\DOWHUWKHVFRUHVZLWKWKHYDULRXVDWWHPSWV
at manipulation of the context or wording of the ques-
tionnaires of VAS. There are a number of limitations 
to the work we present.
Although we studied 215 subjects, we did so in the 
absence of formal power calculations and a type II error 
is always possible. Whereas, if the effect of any biases 
had been major, then we may have detected it, more 
modest effects will probably have gone undetected. 
We cannot rule out clinically relevant effects, although 
our data provide the effect estimates for future studies. 
Secondly, even within the experimental paradigm we 
adopted, there were limitations to the way the experi-
ments were carried out. For instance, although we used 
a video of a child affected by skin disease, we did not 
¿QGDVXLWDEOHYLGHRWKDWZHWKRXJKWZDVPHDQLQJIXO
WRXVHDVDFRQWURO:HDOVRIRXQGLWH[WUHPHO\GLI¿FXOW
to alter the wording of the DLQI without producing a 
caricature of it. The differences seen between the altered 
'/4, DQG WKH JHQXLQH'/4, DSSURDFK VLJQL¿FDQFH
but of course, interpretation of these differences is not 
straightforward. The fact that a different questionnaire 
produces a different median score is not unexpected and, 
HYHQLIWKHGLIIHUHQFHKDGEHHQVLJQL¿FDQWLWGRHVQRW
invalidate, in any way, the use of the DLQI. Another 
facet of this experiment is that it demonstrates that the 
DLQI itself would not appear to bias answering of other 
scores: the GHQ scores were similar whether the parti-
cipants had been exposed to DLQI or to the supposedly 
neutral-framed ADLQI.
Although we have not demonstrated any effects of 
framing or contextual factors in our study, the study 
itself was experimental and may not reproduce the 
VRUWV RI UHDO OLIH IDFWRUV WKDWZLOO LQÀXHQFH WKHZD\
people respond to questionnaires. For instance, and 
rather mundanely, a patient whose appointment has 
been delayed excessively, one can imagine, might be 
considered more likely to weight his or her own disease 
PRUHKHDYLO\,WZRXOGEHGLI¿FXOWWRFDSWXUHVXFKLQÀX-
ences. Furthermore the use of measures such as DLQI as 
MXVWL¿FDWLRQIRUWKHUDS\RUGHQLDORIWKHUDS\DVLQWKH
UK is also much more complex than some appreciate 
(21). Clinical anecdote suggests that patients are quite 
capable of “gaming” the system to achieve what they 
feel are appropriate, and one should remember that 
quality of life, health status and patients’ perception 
RIWKHVHPHDVXUHVDUHGLVWLQFW,WLVGLI¿FXOWQRWWR
imagine that if patients are meaningfully consented, and 
WKHSXUSRVHRI WKH'/4,DVD MXVWL¿FDWLRQRIFOLQLFDO
need is explained, that patients will not moderate their 
answers accordingly.
Finally, it was not our purpose to compare different 
questionnaires, or measures of aspects of diseases. There 
is already a large literature on this and on the advantages 
DQGGLVDGYDQWDJHVRIVSHFLDOLW\RUGLVHDVHVSHFL¿FVFR-
ring systems vs. more generic questionnaires, such as 
Table IV. Experiment 3: subject characteristics, median scores and p-values of Kruskal-Wallis analysis of variance (ANOVA)
Age, years
mean (range)
Sex 
M/F/Un known
Median QI
(interquartile range)
Median GHQ
(interquartile range)
Group 1 (DLQI then GHQ) n = 21 45.1 (28–68) 14/6/1 6.50 (2.75–10.75) 3.00 (2.00–3.00)
Group 2 (GHQ then DLQI) n = 21 42.8 (16–79) 9/11/1 7.00 (4.50–11.00) 2.00 (2.00–3.00)
Group 3 (ADLQI then GHQ) n = 19 42.3 (19–81) 9/9/1 8.00 (6.75–10.50) 2.00 (1.00–3.00)
Group 4 (GHQ then ADLQI) n = 19 44.0 (17–76) 8/11/ 8.50 (6.00–13.50) 2.00 (1.75–3.00)
p = Kruskal-Wallis 0.47 0.76
DLQI: Dermatology Life Quality Index; ADLQI: Amended Dermatology Life Quality Index; GHQ: Global Health Question; QI: Quality of Life Index 
score.
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EuroQOL or SF-36, for instance (22–24). We do feel 
that it is important, however, that in view of the fact 
that there is an increasing literature on the design, use, 
limitations of various disease-scoring systems and on 
cognitive psychology as a whole, that this information 
is acknowledged and used to continue to validate the 
subjective tools that we commonly use.
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